NicOx Blood Pressure Data Positive, But Is it Enough?
This article was originally published in Pharmaceutical Approvals Monthly
Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod
You may also be interested in...
Facing skeptical FDA, company in partnering talks as more Phase III data with anti-inflammatory drug prove positive.
In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.
FDA is adopting a broad range of procedural changes in response to suggestions from outside critics to address drug safety issues. The most significant change, however, may be just a new state of mind.